Oncology and Hematology
49-64 of 246
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Alessandra Tedeschi, MD
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
- MinuteCE®
Winning the Battle Against Side Effects: Adverse Event Management in HSPC
1.00 program creditScott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Chan Y. Cheah, MBBS
Erica L. Mayer, MD, MPH
Aditya Bardia, MD, MPH, FASCO
Aditya Bardia, MD, MPH, FASCO
Aditya Bardia, MD, MPH, FASCO
Erica L. Mayer, MD, MPH
- Oncology and Hematology
DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
Sara A. Hurvitz, MD, FACP
- Oncology and Hematology
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Tiffany Traina, MD
- Oncology and Hematology
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
Sara A. Hurvitz, MD, FACP
